1945 — Andrew J. Moyer at the USDA Peoria Laboratory Filed the Patent for 'Method for Production of Penicillin' US2442141A. Reading the Case in Which the U.S. Department of Agriculture Enclosed as a **Manufacturing-Method Patent** the Discovery That Florey/Chain/Fleming Did Not Patent, from Primary Sources

About excavation memos: "Excavation memos" in this series record candidate summaries at the stage where the primary-source URL has been confirmed. Full-text reading and verbatim verification of all claims have not been performed. Only confirmed facts are recorded; speculation is explicitly marked.

Why dig

Penicillin is one of the most important discoveries in 20th-century pharmaceutical history and the starting point of antibiotic medicine. The golden narrative is widely known: Alexander Fleming's 1928 discovery, Howard Florey/Ernst Chain/Norman Heatley's purification and therapeutic application at Oxford in 1939–1941, and Fleming/Florey/Chain's 1945 Nobel Prize in Physiology or Medicine.

The textbook narrative often says, "Fleming did not take a patent," "Florey and Chain also refused patents," "penicillin was a gift to humanity, never patented." But this is only half accurate. Regarding the manufacturing method, Andrew J. Moyer at the USDA obtained patent US2442141A as sole inventor in 1945–1948, triggering post-war Anglo-American royalty disputes.

The DB row PH-009 in ~/ai-archaeology/db/candidates.tsv lists "Penicillin Mass-Production Patent (Moyer Submerged Culture Method)," "USDA, Andrew J. Moyer (USDA Peoria Laboratory). 1945 filing, 1948 grant," "Not Fleming's discovery patent but a manufacturing process patent. 'Fleming did not take a patent' is accurate but the manufacturing technology was patented" — consistent with the primary source confirmed on Google Patents:

• Patent number US2442141A: Title "Method for production of penicillin," inventor "Andrew J. Moyer" sole (matches DB description), assignee "United States of America, as represented by the Secretary of Agriculture" (USDA = U.S. Department of Agriculture), filed 1945-05-11, granted 1948-05-25. Claim 1 claims a fed-batch culture method with carbon source 5–150 g/L and degraded proteinaceous material 5.0+ g/L, explicitly applied to both surface and submerged culture.

In the consecutive DB-error correction series of Days 8/9/10/11/12 (PH-006), this is the 3rd 'DB-agreement-confirmed' case (after Day 11 aspirin US644077A by Felix Hoffmann and Day 12 ep48 norethindrone US2744122A).

Patent basic information

• Patent number: US2442141A
• Title: Method for production of penicillin
• U.S. filing date (priority date same): May 11, 1945
• U.S. grant date: May 25, 1948
• Inventor: Andrew J. Moyer (sole, residing in Peoria, Illinois, matches DB description)
• Original Assignee: United States of America, as represented by the Secretary of Agriculture
• U.S. expiration: 1965 (17 years from grant)
• Primary source: Google Patents (URL confirmed; title, sole inventor, USDA assignee, filing date, grant date, Claim 1 all obtained)

Core (Google Patents obtained information)

US2442141A Claim 1 (verbatim):

A method for producing penicillin comprising incubating a penicillin-producing mold in contact with an aqueous nutrient medium containing an assimilable carbon source and containing from 5.0 to [g.] of degraded proteinaceous material per liter of medium, a portion of the assimilable carbon source being added at the beginning of the incubation period and additional increments thereof being added during the period to compensate for that used up by the mold, the total amount of assimilable carbon source used being from 5.0 to 150 g. per liter of medium.

The structure claims penicillin production with three elements of culture conditions: (1) assimilable carbon source totaling 5.0–150 g/L (specification examples: lactose, glucose, etc.), (2) degraded proteinaceous material (= corn steep liquor, etc.) 5.0+ g/L, (3) stepwise carbon source addition (some added at the start, additional during the period).

Important points in the specification:

• Culture format: The specification explicitly applies to both surface culture in Fernbach flasks (static culture) and submerged state in tank fermenters (with agitation and aeration). Pfizer's industrialized deep-fermentation tanks at the time are described as application examples of this patent.
• Production strain: This patent exemplifies Penicillium chrysogenum (improved strains such as NRRL 1951.B25), but Claim 1 itself broadly describes "penicillin-producing mold" without restriction to specific strains.
• Heatley's contribution: Norman Heatley's name is not explicitly mentioned in the specification, but the circumstance that Heatley conveyed the Oxford method (surface culture, medium composition) to Moyer during the July 1941 Peoria visit can be confirmed in later historical accounts (Hare 1970, Bud 2007, etc.).

1941 Florey/Heatley Peoria visit

In 1939–1941, Howard Florey/Ernst Chain/Norman Heatley established penicillin purification and therapeutic application at Sir William Dunn School of Pathology, Oxford University, but Britain lacked mass-production capacity under WW2 German bombing. In July 1941, Florey and Heatley visited the U.S. with Rockefeller Foundation support, traveling to New York, Peoria, and Washington, D.C. The Peoria USDA Northern Regional Research Laboratory had Robert D. Coghill (head of fermentation) and Andrew J. Moyer (microbiologist).

Heatley stayed in Peoria for about six months and conveyed the Oxford method to Moyer. Moyer introduced corn steep liquor (a nitrogen-source/vitamin-rich waste liquid from corn-starch production) as a nitrogen and growth-factor source, switching from the Oxford method (sucrose-based medium) to a lactose + corn steep liquor medium. This increased the productivity of Penicillium notatum (Fleming-derived strain) 5–10 fold.

Even more important, in 1943, Mary Hunt ("Moldy Mary") found from the Peoria Penicillium collection that a strain Penicillium chrysogenum NRRL 1951 collected from a Peoria market melon had 34 times higher productivity than the Fleming strain. With X-ray and ultraviolet mutation processing, derivative strains were created, ultimately leading to several hundred-fold productivity improvements.

Establishment of submerged fermentation

Surface culture grows Penicillium statically on the medium surface, with air-contact area limited to the medium surface—unsuitable for mass production. Moyer and colleagues established submerged fermentation in 1942–1944: (a) fill a tank fermenter (agitated, aerated) with medium, (b) suspend Penicillium in liquid with agitation, (c) blow sterile air from the bottom to supply oxygen to cells, (d) 24-hour continuous mass culture.

This submerged fermentation was technology-transferred to U.S. pharmaceutical companies including Pfizer, Merck, Squibb, and Abbott, and U.S. penicillin production expanded several-hundred fold from 1942 to 1945. Monthly production was about 2 billion units in January 1943, reaching 100 billion units monthly by June 1944 (D-Day). Pfizer renovated an old ice factory in Brooklyn in 1944 and operated the world's first large-scale deep-fermentation tanks (14 units, 7,500 gallons each), supplying 2.3 million doses for the Normandy landings.

Claim 1 of US2442141A covers the core of this deep-fermentation technology (stepwise carbon source addition, combined use of degraded proteinaceous material), forming the prehistory of post-war recombinant fermentation, antibody pharmaceuticals, and bioreactor technology.

Nobel Prize vs. patent contrast

In December 1945, Fleming (discovery) / Florey (purification, therapeutic application) / Chain (purification, molecular structural analysis) received the Nobel Prize in Physiology or Medicine. Heatley was excluded from the Nobel Prize (later evaluated with an honorary doctorate of medicine from Oxford in 1990 and U.S. Knighthood). Moyer was also excluded from the Nobel Prize, but received internal USDA recognition with the 1948 patent grant.

Patent holder structure:

• Discovery (Fleming 1928): No patent. The discovery was during his St Mary's Hospital Medical School period in the UK, but Fleming did not patent it.
• Purification and therapeutic application (Florey/Chain 1939–1941): No patent. Florey intentionally refused patenting ("benefit of mankind" principle).
• Manufacturing method (Moyer 1945–1948): US2442141A patented; assignee USDA = U.S. government.

Post-war Britain criticized that "we became royalty payers to the U.S.," but (a) Moyer personally was a federal government employee whose invention was a service invention, (b) USDA used it only internally and did not charge any license fees to Pfizer, etc., (c) Pfizer mass-produced via its own patents improving on Moyer's method. So actual Anglo-American royalty issues were limited (multiple historian assessments, originals not consulted in this article). Still, in British medical circles in the latter half of the 20th century, a reflective narrative circulated: "Florey/Chain's refusal to patent caused Britain to lose the opportunity for industrialization."

Connection to modern (includes speculation)

Notes on reading the table:

Row 1 is identical. The technical lineage of Pfizer's 1944 world-first large-scale deep-fermentation tanks is directly inherited by modern (a) recombinant E. coli insulin production (Eli Lilly Humulin, 1982), (b) CHO cell antibody pharmaceutical production (rituximab etc., 1990s onward), (c) yeast mRNA vaccine intermediate production (Pfizer/BioNTech COVID-19 vaccine, 2020). The paradigm "have organisms produce pharmaceuticals in agitated, aerated fermentation tanks" is an 80-year continuous inheritance of the technology described in US2442141A's Claim 1.

Row 2 is similar. Corn steep liquor + lactose medium optimization was established through trial-and-error and screening from 1942 to 1945, but today is replaced by (a) chemically defined media, (b) DOE (Design of Experiments) statistical optimization, (c) AI-driven medium optimization (GPT systems, genetic algorithms, Bayesian optimization). Problem-consciousness (medium optimization) is identical, but technical means differ, so we keep at "similar."

Row 3 is identical. Fed-batch culture (stepwise nutrient addition) is the core of the technology described in this patent's Claim 1, an early example of culture engineering followed by modern (a) E. coli / CHO cell fed-batch, (b) perfusion culture, (c) continuous fermentation.

Row 4 is identical. The structure where USDA owns federal employee Moyer's invention is directly inherited by modern (a) NIH internal research patent ownership, (b) DOE national laboratory (Lawrence Berkeley, Argonne, etc.) patent strategy, (c) NASA technology transfer programs. This 1948-granted patent is one of the early examples of the federal patent ownership model.

Row 5 is identical. The three-layer contributor separation (Fleming's discovery / Florey, Chain's purification, therapeutic application / Moyer's manufacturing method) is an early example of differentiation of substance patents vs. use patents vs. manufacturing-method patents in modern pharmaceutical patent strategy.

Row 6 is similar. The 1944 D-Day mass supply of penicillin and the 2020 COVID-19 mRNA vaccine Operation Warp Speed (a U.S. government-led emergency pharmaceutical production program) overlap as wartime/emergency pharmaceutical mass-production models in problem-consciousness.

Row 7 is similar. The 1945 Nobel Prize was three (Fleming/Florey/Chain), with Heatley and Moyer excluded, but the manufacturing-method patent is Moyer alone. "Mismatch between Nobel-Prize and patent holders" continues today (e.g., Doudna/Charpentier Nobel Chemistry 2020 for CRISPR/Cas9 vs. Broad Institute Zhang lab patents).

Row 8 is similar. Mary Hunt's Penicillium chrysogenum strain from a Peoria market melon is an early example of 1943 bioprospecting. Problem-consciousness continues with modern (a) marine biological resource exploration (marine natural product drug discovery), (b) soil metagenomic analysis (gene exploration of uncultured microorganisms), (c) extreme-environment microorganism antibiotic exploration (deep-sea hydrothermal vents, Antarctic ice sheets, etc.).

Why this is worth digging

Reason 1: Precise narrative of "Fleming did not take a patent"

The story "Fleming/Florey/Chain did not take patents" / "penicillin was a gift to humanity" is widely circulated in popular science, but precision is needed in three layers: (a) the discovery patent (Fleming) was indeed not obtained, (b) the purification and therapeutic application patent (Florey/Chain) was intentionally refused, (c) the manufacturing-method patent (Moyer) was obtained by USDA in 1945–1948. The existence of the manufacturing-method patent is often unmentioned in popular science books.

Reason 2: Anglo-American post-war patent history

Post-war Britain circulated a reflective narrative that "Florey/Chain's refusal to patent caused Britain to lose the opportunity for industrialization," but actually (a) the Moyer method was USDA-owned with limited license fee charging to Pfizer, etc., (b) Britain established its own manufacturing methods at Beecham, Glaxo, and Wellcome by 1947, (c) in 1959 Beecham's semisynthetic penicillin (methicillin, ampicillin) patents reversed the British side—the Anglo-American penicillin patent history is not a simple "British defeat."

Reason 3: Prehistory of 80 years of submerged culture technology

The stepwise carbon source addition (fed-batch culture) of US2442141A's Claim 1 is the core technology of culture engineering that has continued for 80 years from Pfizer's large-scale tanks in 1944 to mRNA vaccine production in 2020. This patent expired in the U.S. in 1965, but all subsequent recombinant fermentation, antibody pharmaceuticals, and mRNA vaccine production are on this technology lineage.

Pitfalls

Pitfall 1: "Moyer personally owned the patent" is wrong

Moyer was a federal government employee (USDA Northern Regional Research Laboratory microbiologist), and this invention was a service invention owned by USDA = U.S. government. There is no fact that Moyer personally received royalties. "Moyer personal patent" is wrong; the assignee is "United States of America, as represented by the Secretary of Agriculture."

Pitfall 2: "Fleming strain = mass production strain" is wrong

The Penicillium notatum strain Fleming discovered in 1928 had low productivity and was unsuitable for mass production. Penicillium chrysogenum NRRL 1951, which Mary Hunt collected from a Peoria market melon in 1943, had 34 times higher productivity than the Fleming strain, and X-ray and ultraviolet mutation processing was used to create derivatives (NRRL 1951.B25, etc.), ultimately leading to several hundred-fold productivity improvements. "Fleming's strain made the world's penicillin" is a myth; in fact, the Peoria melon strain is the ancestor of modern production strains.

Pitfall 3: "Simple transition from surface to submerged culture" is oversimplification

The development at Peoria from 1942 to 1944 was a 4-step continuous optimization—surface culture (Oxford method) → shake flask culture → small tank submerged → large tank submerged—with adjustments needed for medium composition, aeration rate, agitation speed, temperature, and pH at each step. When Pfizer operated 14 units of 7,500-gallon tanks in 1944, productivity varied greatly across tanks, and quality control (biological assay methods in the era before HPLC) was established in parallel.

Pitfall 4: "penicillin G = modern penicillin" is oversimplification

US2442141A describes the manufacturing method for penicillin G (benzylpenicillin, the first natural penicillin), and modern mainstream (a) penicillin V (oral phenoxymethylpenicillin, acid-resistant), (b) ampicillin (broad-spectrum), (c) methicillin (resistance-resistant), (d) amoxicillin (oral broad-spectrum) are all semisynthetic from 6-aminopenicillanic acid (6-APA) produced by Moyer's method, and were derived in 1959–1962 onward. This patent is the manufacturing method for natural penicillin G, and modern penicillin-class drugs are technically positioned as derivative generations.

Strictly speaking

Confirmed facts

From Google Patents: US2442141A / Title "Method for production of penicillin" / Inventor "Andrew J. Moyer" sole (matches DB, Peoria, Illinois resident) / Original Assignee "United States of America, as represented by the Secretary of Agriculture" / Filing date 1945-05-11 / Priority date 1945-05-11 / Grant date 1948-05-25 / U.S. expiration 1965 (17 years from grant) / Claim 1 verbatim obtained (penicillin-producing mold + assimilable carbon source 5–150 g/L + degraded proteinaceous material 5.0+ g/L + stepwise carbon source addition) / Specification explicitly applies to both surface culture (Fernbach flasks) and submerged culture (tank fermenters) / 1945 Fleming/Florey/Chain Nobel Prize in Physiology or Medicine (Nobel Prize official records).

Author's interpretation

"July 1941 Florey/Heatley Peoria visit," "Heatley conveyed the Oxford method to Moyer," "5–10 fold productivity improvement from corn steep liquor + lactose medium switch," "34-fold improvement from Mary Hunt's 1943 melon-collected strain NRRL 1951," "several hundred-fold improvement via X-ray and ultraviolet mutation processing," "2.3 million dose supply for D-Day in 1944," "operation of Pfizer's 14 units of 7,500-gallon tanks in 1944," "Florey intentionally refused patenting," "post-war British reflective narrative" — these are author's interpretations / secondary-source-derived information. Widely known via history books such as Hare 1970 The Birth of Penicillin, Bud 2007 Penicillin: Triumph and Tragedy, Bickel 1972 Rise Up to Life: A Biography of Howard Walter Florey Who Made Penicillin and Gave It to the World, but originals not consulted in this article.

Metaphors / analogies

Row 2 of the table (corn steep liquor empirical optimization vs. modern AI-driven medium optimization) is similar. Medium optimization problem-consciousness continues, but technical means (experience vs. AI) differ, so we keep at "similar." Row 6 (D-Day penicillin mass supply vs. Operation Warp Speed COVID-19 vaccine) is similar. We arrange them as wartime/emergency pharmaceutical mass-production models, but technical fields (fermentation vs. mRNA) differ. Row 7 (Fleming Nobel Prize vs. Moyer patent) is similar. We arrange them as Nobel Prize vs. patent holder mismatch, but the target research (discovery vs. manufacturing method) differs. Row 8 (Mary Hunt melon collection vs. modern bioprospecting) is similar. Biological resource exploration problem-consciousness continues, but technical means (market purchase vs. metagenomic analysis) differ.

Unconfirmed

Verbatim verification of the full Description text of US2442141A / full text of Claims 2 and onward / the upper concentration character for degraded proteinaceous material in Claim 1 (the part that displayed as "[g.]" due to OCR garbling) / Moyer's USDA tenure records / Heatley's 1941–1942 Peoria stay records / Florey's July 1941 U.S. visit itinerary and meeting records / Coghill's involvement records as USDA Peoria fermentation department head / official records of Mary Hunt's 1943 Penicillium chrysogenum NRRL 1951 from Peoria melon / X-ray and ultraviolet mutation processing protocols / Pfizer 1944 Brooklyn factory's 14 units of 7,500-gallon tank details / source for the 2.3 million unit penicillin dose for D-Day in 1944 / originals of Hare 1970 / Bud 2007 / Bickel 1972 history books / 1945 Fleming/Florey/Chain Nobel lecture originals / British parliamentary records on post-war Anglo-American royalty issues / comparison with 1959–1962 Beecham semisynthetic penicillin patent group (methicillin US3007918, etc.).

Where this comparison breaks down

US2442141A is a 1945-filing penicillin manufacturing-method patent, and modern recombinant fermentation, antibody pharmaceuticals, and mRNA vaccine manufacturing differ fundamentally in scale, target organism, and product. Connecting "Moyer's submerged culture = modern bioreactors" directly invites multiple objections from experts: (1) Pfizer's 1944 tanks were 7,500 gallons; modern CHO cell antibody production is on the scale of tens of thousands of L, with significant technical evolution, (2) target organisms changed from Penicillium (fungi) to recombinant E. coli, CHO cells, yeast, (3) products expanded from natural penicillin G to recombinant proteins, antibodies, mRNA, siRNA. The narrative "Moyer's patent is the ancestor of all modern pharmaceutical production" is appealing on the time-scale axis, but technically only the core elements of submerged fermentation tank + fed-batch culture are inherited; other technologies (cell strains, gene recombination, purification process) are separate lineages. The story "Fleming/Florey/Chain did not take patents" is only half accurate; the manufacturing-method patent was obtained by USDA. The excavation memo is limited to Google Patents range confirmation; Heatley's Peoria stay records, Pfizer factory records, history book originals, and the 1959–1962 Beecham semisynthetic penicillin patent group are not obtained—these limits are stated explicitly.

References:

• Original patent: US2442141A on Google Patents
• Related excavation note (Pharmaceutical Patents #4): Syntex Djerassi/Miramontes/Rosenkranz norethindrone US2744122A (1951, Mexico)
• Related excavation memo #4 (Pharmaceutical Patents): Pfizer Bell/Brown/Terrett sildenafil US5250534A (1990)
• Related excavation note (Pharmaceutical Patents #3): Squibb Ondetti & Cushman ACE inhibitor (captopril) two-series patents
• Related excavation note (Pharmaceutical Patents #2): Köhler & Milstein monoclonal antibody (1975 Nature) + Wistar US4172124A
• Related excavation note (Pharmaceutical Patents #1): Cetus PCR core patent US4683195A (1985)